Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis - a prospective follow-up study

Clin Chem Lab Med. 2022 May 2;60(7):1124-1132. doi: 10.1515/cclm-2022-0097. Print 2022 Jun 27.

Abstract

Objectives: The purpose of this study was to evaluate levels and kinetics of cerebrospinal fluid (CSF) markers of inflammation and brain injury in patients with Lyme neuroborreliosis (LNB).

Methods: Adult patients with clinically suspected LNB were enrolled, in a prospective clinical study in the South East of Sweden. Patients were classified according to the European Federation of Neurological Societies' guidelines. Definite cases of LNB were re-examined one month later including a repeat CSF investigation. Routine laboratory parameters were investigated along with CSF levels of neurodegenerative markers glial fibrillary acidic protein (GFAp), total tau (t-tau) and neurofilament light protein (NFL), as well as neuroinflammatory markers soluble triggering receptor expressed on myeloid cells 2 (sTREM2), YKL-40 and CXCL13. Non-LNB served as controls. An additional comparison group consisted of spinal anesthesia subjects (SAS) without known central nervous system conditions.

Results: CSF levels of sTREM2 and CXCL13 were elevated in definite LNB patients at diagnosis compared with non-LNB patients (p<0.001) and SAS (p≤0.01). In addition, CSF levels of sTREM2, YKL-40 and CXCL13 rapidly declined in at follow-up after antibiotic treatment. In contrast, CSF levels of GFAp and t-tau did not differ across LNB groups, and did not change after treatment.

Conclusions: Although in a limited number of LNB patients, the results indicate a predominance of microglial and neuroinflammatory involvement rather than parenchymal CNS injury in CSF at diagnosis of LNB with a prompt decline after antibiotic treatment. The findings provide pathogenetic insights and may be of value in differential diagnosis of CSF findings.

Keywords: Lyme neuroborreliosis; biomarkers; brain injury; cerebrospinal fluid; pathogenesis.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Biomarkers / cerebrospinal fluid
  • Brain Injuries*
  • Chitinase-3-Like Protein 1
  • Follow-Up Studies
  • Humans
  • Inflammation / drug therapy
  • Lyme Neuroborreliosis* / cerebrospinal fluid
  • Lyme Neuroborreliosis* / diagnosis
  • Prospective Studies

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • Chitinase-3-Like Protein 1